These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37806792)

  • 21. Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis.
    Maher RE; Barry PJ; Emmott E; Jones AM; Lin L; McNamara PS; Smith JA; Lord RW
    J Cyst Fibros; 2024 Mar; 23(2):269-277. PubMed ID: 37951788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
    Terlizzi V
    J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
    [No Abstract]   [Full Text] [Related]  

  • 23. Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert's syndrome.
    Weitzel J; Welsner M; Taube C; Ballmann M; Sutharsan S
    BMC Pulm Med; 2024 Jul; 24(1):307. PubMed ID: 38956524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.
    Gonçalves Martynychen Canan M; Souza Sokoloski C; Rossetti Severo C; Zahi Rached S; Abensur Athanazio R
    Arch Bronconeumol; 2024 Aug; 60(8):526-528. PubMed ID: 38714384
    [No Abstract]   [Full Text] [Related]  

  • 25. Year in review 2023 - Back to the future.
    Cristiani L; Fernandes FF
    J Cyst Fibros; 2024 Mar; 23(2):203-207. PubMed ID: 38431442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abdominal Symptoms Assessed With the CFAbd-Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis.
    Jaudszus A; Pfeifer E; Lorenz M; Beiersdorf N; Hipler UC; Zagoya C; Mainz JG
    J Pediatr Gastroenterol Nutr; 2022 Mar; 74(3):355-360. PubMed ID: 34789668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment.
    Castaldo A; Iacotucci P; Bagnasco S; Fevola C; Carnovale V; Antonelli F; Cernera G; Gelzo M; Terlizzi V
    Sci Rep; 2024 Jul; 14(1):17422. PubMed ID: 39075279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study.
    Wiesel V; Aviram M; Mei-Zahav M; Dotan M; Prais D; Cohen-Cymberknoh M; Gur M; Bar-Yoseph R; Livnat G; Goldbart A; Hazan G; Hazan I; Golan-Tripto I
    J Cyst Fibros; 2024 Jan; 23(1):41-49. PubMed ID: 37173154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation.
    Taylor-Cousar JL; Jain R
    J Cyst Fibros; 2021 May; 20(3):402-406. PubMed ID: 33762125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant.
    Coman D; Vincent C; Huard G; Marleau D; Lavoie A; Hercun J
    J Cyst Fibros; 2024 May; 23(3):561-562. PubMed ID: 38000917
    [No Abstract]   [Full Text] [Related]  

  • 35. Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series.
    O'Connor KE; Goodwin DL; NeSmith A; Garcia B; Mingora C; Ladores SL; Rowe SM; Krick S; Solomon GM
    J Cyst Fibros; 2021 May; 20(3):399-401. PubMed ID: 33353860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reply to Piehler
    Duff AJA; Lee TWR
    Am J Respir Crit Care Med; 2024 Aug; 210(3):367. PubMed ID: 38843537
    [No Abstract]   [Full Text] [Related]  

  • 37. Longitudinal Evaluation of Bronchial Changes in Cystic Fibrosis Patients Undergoing Elexacaftor/Tezacaftor/Ivacaftor Therapy Using Lung MRI With Ultrashort Echo-Times.
    David M; Benlala I; Bui S; Benkert T; Berger P; Laurent F; Macey J; Dournes G
    J Magn Reson Imaging; 2024 Jul; 60(1):116-124. PubMed ID: 37861357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
    Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
    J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
    James A; Li G; List R; Lonabaugh K; Smith AD; Barros A; Somerville L; Albon D
    Pediatr Pulmonol; 2024 Mar; 59(3):669-678. PubMed ID: 38088203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study.
    Donaldson SH; Corcoran TE; Pilewski JM; Laube BL; Mogayzel P; Ceppe A; Wu J; Zeman K; Rowe SM; Nichols DP; Gifford AH; Bennett WD; Mayer-Hamblett N;
    J Cyst Fibros; 2024 May; 23(3):457-460. PubMed ID: 38355350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.